Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TERT | O14746 | 1/20 | 0.41 |
| ▸ | ACP1 | P24666 | 1/20 | 0.40 |
| ▸ | CXCR3 | P49682 | 4/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | PAK3 | O75914 | 1/20 | 0.37 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.37 |
| ▸ | PAK2 | Q13177 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4270711 | 1.00 | HTR1A (0.43) | HTR1ADRD2DRD3KDRLMNA | |
| SCHEMBL4270712 | 1.00 | HTR1A (0.43) | HTR1ADRD2DRD3KDRLMNA | |
| SCHEMBL4279707 | 1.00 | HTR1A (0.43) | HTR1ADRD2DRD3KDRLMNA | |
| SCHEMBL4270706 | 1.00 | HTR1A (0.43) | HTR1ADRD2DRD3KDRLMNA | |
| SCHEMBL4274244 | 1.00 | HTR1A (0.43) | HTR1ADRD2DRD3KDRLMNA | |
| SCHEMBL4274250 | 1.00 | HTR1A (0.43) | HTR1ADRD2DRD3KDRLMNA | |
| SCHEMBL4276679 | 0.97 | HTR1A (0.41) | HTR1ADRD2DRD3KDRLMNA | |
| SCHEMBL4276666 | 0.97 | HTR1A (0.41) | HTR1ADRD2DRD3KDRLMNA | |
| SCHEMBL4276672 | 0.97 | HTR1A (0.41) | HTR1ADRD2DRD3KDRLMNA | |
| SCHEMBL8374288 | 0.92 | HTR1A (0.40) | HTR1ADRD2DRD3KDRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298834-A1 | 4-(AMINOMETHYL)CYCLOHEXANAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-12-03 | — | — | US | disclosed |
| US-20090298834-A1 | 4-(AMINOMETHYL)CYCLOHEXANAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298834-A1 | 4-(AMINOMETHYL)CYCLOHEXANAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1I, CACNA1H | HTR1A 258/4885DRD2 416/4885DRD3 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.